| pubmed-article:17541592 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17541592 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:17541592 | lifeskim:mentions | umls-concept:C0032207 | lld:lifeskim |
| pubmed-article:17541592 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:17541592 | lifeskim:mentions | umls-concept:C1142934 | lld:lifeskim |
| pubmed-article:17541592 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:17541592 | lifeskim:mentions | umls-concept:C1709630 | lld:lifeskim |
| pubmed-article:17541592 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17541592 | pubmed:dateCreated | 2007-7-19 | lld:pubmed |
| pubmed-article:17541592 | pubmed:abstractText | Satraplatin is an orally available platinum analog. The purpose of this study was to better characterize satraplatin's preclinical antitumor efficacy in a variety of sensitive and resistant human tumor cell lines and in a prostate cancer xenograft model and to evaluate the effect of satraplatin on PSA expression and/or secretion in a prostate cancer cell line. | lld:pubmed |
| pubmed-article:17541592 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17541592 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17541592 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17541592 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17541592 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17541592 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17541592 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17541592 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17541592 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17541592 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17541592 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:17541592 | pubmed:author | pubmed-author:WosikowskiKat... | lld:pubmed |
| pubmed-article:17541592 | pubmed:author | pubmed-author:RattelBennoB | lld:pubmed |
| pubmed-article:17541592 | pubmed:author | pubmed-author:JungVolkerV | lld:pubmed |
| pubmed-article:17541592 | pubmed:author | pubmed-author:UntereggerGer... | lld:pubmed |
| pubmed-article:17541592 | pubmed:author | pubmed-author:CaligiuriMaur... | lld:pubmed |
| pubmed-article:17541592 | pubmed:author | pubmed-author:KaplanFaithF | lld:pubmed |
| pubmed-article:17541592 | pubmed:author | pubmed-author:XuJimmy PJP | lld:pubmed |
| pubmed-article:17541592 | pubmed:author | pubmed-author:LamphereLouL | lld:pubmed |
| pubmed-article:17541592 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17541592 | pubmed:volume | 60 | lld:pubmed |
| pubmed-article:17541592 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17541592 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17541592 | pubmed:pagination | 589-600 | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:meshHeading | pubmed-meshheading:17541592... | lld:pubmed |
| pubmed-article:17541592 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17541592 | pubmed:articleTitle | Preclinical antitumor activity of the oral platinum analog satraplatin. | lld:pubmed |
| pubmed-article:17541592 | pubmed:affiliation | From GPC Biotech, Fraunhoferstrasse 20, 82152 Martinsried/Munich, Germany. Katja.wosikowski@gpc-biotech.com | lld:pubmed |
| pubmed-article:17541592 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17541592 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17541592 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17541592 | lld:pubmed |
